ReviewMediators of inflammation2014
TNF blocking therapies and immunomonitoring in patients with inflammatory bowel disease.
Review in Mediators of inflammation, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 1 synthesis or guideline pooled it, 30 citations in OpenAlex.
- Correlations between TLR polymorphisms and inflammatory bowel disease: a meta-analysis of 49 case-control studies.Immunologic research · 2019Pooled it
- Efficacy of vedolizumab as maintenance therapy in a patient with ulcerative colitis receiving haemodialysis in end-stage kidney failure: A case report.SAGE open medical case reports · 2023Article
- Stem Cell-Based Therapies for Inflammatory Bowel Disease.International journal of molecular sciences · 2022Review
- Real-world clinical effectiveness and safety of vedolizumab and anti-tumor necrosis factor alpha treatment in ulcerative colitis and Crohn's disease patients: a German retrospective chart review.BMC gastroenterology · 2020Article
- Long-range PCR libraries and next-generation sequencing for pharmacogenetic studies of patients treated with anti-TNF drugs.The pharmacogenomics journal · 2019Article
- Phytotherapies in inflammatory bowel disease.Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences · 2019Review
- Succinylated chitosan derivative has local protective effects on intestinal inflammation.ACS biomaterials science & engineering · 2017Article
- Multiscale analysis of the murine intestine for modeling human diseases.Integrative biology : quantitative biosciences from nano to macro · 2015Article
- Botanical Drugs as an Emerging Strategy in Inflammatory Bowel Disease: A Review.Mediators of inflammation · 2015Review
- Tumour necrosis factor superfamily members in the pathogenesis of inflammatory bowel disease.Mediators of inflammation · 2014Review
- S1P signaling: new therapies and opportunities.F1000prime reports · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Since their appearance in the armamentarium for inflammatory bowel disease (IBD) more than a decade ago, antitumor necrosis factor (TNF) inhibitors have demonstrated beneficial activity in induction and maintenance of clinical remission, mucosal healing, improvement in quality of life, and reduction in surgeries and hospitalizations. However, more than one-third of patients present primary resistance, and another one-third become resistant over time. One of the main factors associated with loss of response is the immunogenicity of anti-TNF biologics leading to the production of antidrug antibodies (ADAbs) accelerating their clearance. In this review we present the current state of the literature on the place of TNF and its blockage in the treatment of patients with IBD and discuss the usefulness of serum trough levels and ADAb monitoring in the optimization of anti-TNF therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.